These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 23963965)

  • 1. An open-label, rater-blinded, 8-week trial of bupropion hydrochloride extended-release in patients with major depressive disorder with atypical features.
    Seo HJ; Lee BC; Seok JH; Jeon HJ; Paik JW; Kim W; Kwak KP; Han C; Lee KU; Pae CU
    Pharmacopsychiatry; 2013 Sep; 46(6):221-6. PubMed ID: 23963965
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Eight-week, placebo-controlled, double-blind comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR.
    Hewett K; Chrzanowski W; Schmitz M; Savela A; Milanova V; Gee M; Krishen A; Millen L; Leary MO; Modell J
    J Psychopharmacol; 2009 Jul; 23(5):531-8. PubMed ID: 18635695
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bupropion extended release compared with escitalopram: effects on sexual functioning and antidepressant efficacy in 2 randomized, double-blind, placebo-controlled studies.
    Clayton AH; Croft HA; Horrigan JP; Wightman DS; Krishen A; Richard NE; Modell JG
    J Clin Psychiatry; 2006 May; 67(5):736-46. PubMed ID: 16841623
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Double-blind, placebo-controlled comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR.
    Hewett K; Gee MD; Krishen A; Wunderlich HP; Le Clus A; Evoniuk G; Modell JG
    J Psychopharmacol; 2010 Aug; 24(8):1209-16. PubMed ID: 19939870
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
    Detke MJ; Wiltse CG; Mallinckrodt CH; McNamara RK; Demitrack MA; Bitter I
    Eur Neuropsychopharmacol; 2004 Dec; 14(6):457-70. PubMed ID: 15589385
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Extended-release bupropion for patients with major depressive disorder presenting with symptoms of reduced energy, pleasure, and interest: findings from a randomized, double-blind, placebo-controlled study.
    Jefferson JW; Rush AJ; Nelson JC; VanMeter SA; Krishen A; Hampton KD; Wightman DS; Modell JG
    J Clin Psychiatry; 2006 Jun; 67(6):865-73. PubMed ID: 16848645
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients.
    Yevtushenko VY; Belous AI; Yevtushenko YG; Gusinin SE; Buzik OJ; Agibalova TV
    Clin Ther; 2007 Nov; 29(11):2319-32. PubMed ID: 18158074
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and tolerability of extended release quetiapine fumarate monotherapy as maintenance treatment of major depressive disorder: a randomized, placebo-controlled trial.
    Liebowitz M; Lam RW; Lepola U; Datto C; Sweitzer D; Eriksson H
    Depress Anxiety; 2010 Oct; 27(10):964-76. PubMed ID: 20734365
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Double-blind, placebo-controlled evaluation of extended-release bupropion in elderly patients with major depressive disorder.
    Hewett K; Chrzanowski W; Jokinen R; Felgentreff R; Shrivastava RK; Gee MD; Wightman DS; O'Leary MC; Millen LS; Leon MC; Briggs MA; Krishen A; Modell JG
    J Psychopharmacol; 2010 Apr; 24(4):521-9. PubMed ID: 19164492
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An open-label, rater-blinded, flexible-dose, 8-week trial of escitalopram in patients with major depressive disorder with atypical features.
    Pae CU; Masand PS; Peindl K; Mannelli P; Han C; Marks DM; Patkar AA
    Prim Care Companion J Clin Psychiatry; 2008; 10(3):205-10. PubMed ID: 18615172
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does early-onset chronic or recurrent major depression impact outcomes with antidepressant medications? A CO-MED trial report.
    Sung SC; Wisniewski SR; Balasubramani GK; Zisook S; Kurian B; Warden D; Trivedi MH; Rush AJ;
    Psychol Med; 2013 May; 43(5):945-60. PubMed ID: 23228340
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of bupropion SR on specific symptom clusters of depression: analysis of the 31-item Hamilton Rating Scale for depression.
    Jamerson BD; Krishnan KR; Roberts J; Krishen A; Modell JG
    Psychopharmacol Bull; 2003; 37(2):67-78. PubMed ID: 14566216
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved insomnia symptoms and sleep-related next-day functioning in patients with comorbid major depressive disorder and insomnia following concomitant zolpidem extended-release 12.5 mg and escitalopram treatment: a randomized controlled trial.
    Fava M; Asnis GM; Shrivastava RK; Lydiard B; Bastani B; Sheehan DV; Roth T
    J Clin Psychiatry; 2011 Jul; 72(7):914-28. PubMed ID: 21208597
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aripiprazole augmentation versus antidepressant switching for patients with major depressive disorder: A 6-week, randomized, rater-blinded, prospective study.
    Han C; Wang SM; Kwak KP; Won WY; Lee H; Chang CM; Tang TC; Pae CU
    J Psychiatr Res; 2015; 66-67():84-94. PubMed ID: 26013203
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A double-blind comparison between bupropion XL and venlafaxine XR: sexual functioning, antidepressant efficacy, and tolerability.
    Thase ME; Clayton AH; Haight BR; Thompson AH; Modell JG; Johnston JA
    J Clin Psychopharmacol; 2006 Oct; 26(5):482-8. PubMed ID: 16974189
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Open trial of bupropion SR in adolescent major depression.
    Glod CA; Lynch A; Flynn E; Berkowitz C; Baldessarini RJ
    J Child Adolesc Psychiatr Nurs; 2003; 16(3):123-30. PubMed ID: 14603988
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.
    Tourian KA; Padmanabhan SK; Groark J; Brisard C; Farrington D
    Clin Ther; 2009 Jun; 31 Pt 1():1405-23. PubMed ID: 19698901
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A multicenter evaluation of the efficacy and safety of 150 and 300 mg/d sustained-release bupropion tablets versus placebo in depressed outpatients.
    Reimherr FW; Cunningham LA; Batey SR; Johnston JA; Ascher JA
    Clin Ther; 1998; 20(3):505-16. PubMed ID: 9663366
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of prolonged-release trazodone in major depressive disorder: a multicenter, randomized, double-blind, flexible-dose trial.
    Zhang L; Xie WW; Li LH; Zhang HG; Wang G; Chen DC; Cao Y; Cui LJ; Zhang KR; Shi JG; Tan QR; Zheng HB; Xu XF; Cheng ZH; Zhao JP
    Pharmacology; 2014; 94(5-6):199-206. PubMed ID: 25376160
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and tolerability of venlafaxine extended release in patients with major depressive disorder.
    Plesnicar BK
    Psychiatr Danub; 2010 Sep; 22(3):413-7. PubMed ID: 20856184
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.